EUCTR2020-005961-16-DK进行中（未招募）1 期
Coenzyme Q10 as treatment for Long Term COVID-19 (The QVID study) - QVID study
ars Jørgen Østergaard0 个研究点目标入组 120 人开始时间: 2020年12月15日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Age above 18 years.
- •2.Able to give informed consent.
- •3.History of documented SARS-CoV-2 infection either by RT-PCR or antibody test.
- •4.Symptoms related to LTC, defined as being investigated, diagnosed and followed by specialized infectious diseases physicians in the Long Term COVID-19 Outpatient Clinic, Central Region of Denmark, Aarhus University Hospital. This clinic covers all LTC patients referred from general practitioners and regional hospitals in Region Midtjylland.
- •5. Symptoms not attributable to other co-morbidity/condition.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1.Symptoms of acute COVID-19, as defined by The Danish Health Authorities/Sundhedsstyrelsen.
- •2.Pregnant or breast-feeding women.
- •3.Known allergy to soy or peanuts.
- •4.Individuals with reduced kidney or liver-function.
- •5.Patients in anticoagulant therapy with warfarin or similar vitamin K antagonists.
- •6.Any condition that, in the Investigator's opinion, will prevent adequate compliance with study therapy.
研究者
相似试验
已完成
不适用
Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide [BNP]), and long-term outcome (hospitalisations/mortality)Chronic heart failureISRCTN94506234Pharma Nord ApS (Denmark)550
进行中（未招募）
不适用
Coenzyme Q10 as adjunctive treatment of chronic heart failure. A randomised double-blind multicenter trial with focus on Symptoms, Biomarker status (BNP) and long-term Outcome (hospitalisation/mortality).(Q-Symbio). - Q-SYMBIOChronic heart failure for more than 6 weeks, in NYHA class III or IV. Age>18 yearsmales and females. Optimal medical treatment of heart failure according to the investigators opinion.EUCTR2005-002960-27-HUPharma Nord ApS550
已完成
2 期
Treatment outcome of Co-enzyme Q10 on infertilityMale infertility.male infertilityIRCT201110034181N7Tabriz university of medical sciences50
已完成
2 期
Effect of supplementation in treatment of patients with polycystic ovary syndromePolycystic ovary syndrome.Polycystic ovary syndromeIRCT201612315623N97Vice chancellor of research, Bushehr University of Medical Sciences40
已完成
3 期
Effect of supplementation in treatment of patients with diabetic nephropathyDiabetic nephropathy.Glomerular disorders in diabetes mellitus (E10-E14 with common fourth character .2+)N08.3IRCT201606205623N85Vice chancellor for research, Kashan University of Medical Sciences50